Peri-myocarditis caused by topical rectal mesalamine

Koslowsky, Benjamin; Orlev, Amir

doi:10.1007/s12328-021-01341-6

Cited by 4 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current evidence, however, shows that NAT1 and NAT2 genotypes do not predict response or toxicity to mesalazine and sulfasalazine in UC patients 16. This is consistent with low-dose oral and rectal mesalazine, whose bioavailability is comparable (around 20%), being shown to cause peri/myocarditis 17. These findings are not surprising, given the immune nature of the adverse effect mechanisms described.…”

Section: Discussionmentioning

confidence: 59%

Drug-induced hypersensitivity syndrome with lupus manifestations due to mesalazine in a patient with ulcerative colitis

et al. 2022

View full text Add to dashboard Cite

Mesalazine is often used as first-line therapy for ulcerative colitis. Several reports have pointed to systemic adverse reactions associated with this drug. Most have evoked a drug-induced hypersensitivity syndrome, while some have described lupus syndromes but with limited clinical and varied biological features. A 75-year-old man presented with fever, dyspnoea, chest pain, polyarthralgia, and myalgia, following mesalazine introduction. Clinical symptoms and low-titre positive antihistone antibodies disappeared after mesalazine withdrawal without recourse to steroids. Pericardial effusion and 8F-fluorodeoxyglucose uptake on positron emission tomography/CT scan, and glomerular haematuria and proteinuria also disappeared. Cytokine-lymphocyte transformation tests showed a strong sensitisation pattern with interleukin-5 production. This case advances our knowledge of the mechanism of mesalazine-induced adverse effects, namely via drug-induced hypersensitivity with lupus manifestations, which we are the first to report.

show abstract

Section: Discussionmentioning

confidence: 59%

Drug-induced hypersensitivity syndrome with lupus manifestations due to mesalazine in a patient with ulcerative colitis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…We identified additional cases of pericarditis, myocarditis, or pleuropericarditis induced by medications used in the treatment of pediatric IBD in adult patients with inflammatory diseases including adalimumab [42,43], etanercept [44], azathioprine [45], methotrexate (MTX) [46], and topical rectal mesalamine [47].…”

Section: Review Prevalence and Etiology Of Pericarditis And Myocardit...mentioning

confidence: 99%

A Review of Extraintestinal Manifestations & Medication-Induced Myocarditis and Pericarditis in Pediatric Inflammatory Bowel Disease

Cesa¹,

Cunningham²,

Harris³

et al. 2022

Cureus

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a systemic disorder where extraintestinal symptoms may involve virtually any organ system. Of these extraintestinal symptoms, those involving the heart are relatively rare but associated with significant morbidity. We reviewed the existing literature on noninfectious myocarditis and pericarditis in the pediatric IBD population, including extraintestinal manifestations (EIMs) of IBD and extraintestinal complications (EICs) from medication. We focused on the incidence, presentation, diagnosis, treatment, and outcomes for timely diagnosis and management of these potentially deadly diseases. In addition, we aim to identify and highlight the gaps in current knowledge for future studies and investigations.

show abstract

Mesalazine

2021

Reactions Weekly

View full text Add to dashboard Cite

Peri-myocarditis caused by topical rectal mesalamine

Cited by 4 publications

References 13 publications

Drug-induced hypersensitivity syndrome with lupus manifestations due to mesalazine in a patient with ulcerative colitis

Drug-induced hypersensitivity syndrome with lupus manifestations due to mesalazine in a patient with ulcerative colitis

A Review of Extraintestinal Manifestations & Medication-Induced Myocarditis and Pericarditis in Pediatric Inflammatory Bowel Disease

Mesalazine

Contact Info

Product

Resources

About